image
image
  • Home
  • About us
  • Journals
  • Guidelines
    • Author Guidelines
    • Editor Guidelines
    • Reviewer Guidelines
  • Article Submission
  • Join as Editor
  • Join as Reviewer
  • contact
    • Login
    • Register
  • Login
  • Register

EC Cancer

Editorial Board

Deepavali Chakravarti, The University of Texas MD Anderson Cancer Center., USA

Priya Bhosale,  The University of Texas MD Anderson Cancer Center., USA

Reham Abdel-Wahab,  The University of Texas MD Anderson Cancer Center., USA

Shilpa S Dhar,  The University of Texas MD Anderson Cancer Center., USA

Emad Shash,  Cairo University, Egypt

Yunlong Qin,  Morehouse School of Medicine, USA

Carlos Encarnacion,  Texas Oncology, USA

Jun-Jie Chen,  I Shou University, Taiwan

Michael J Gonzalez,  University of Puerto Rico, USA

Anupam Bishayee,  Larkin Health Sciences Institute, USA

Mahmoud Abdelhalim Salama,  Northwestern University, USA

Antonio Giordano,  Temple University, USA

Gamal Abdul Hamid,  National Oncology Center, Yemen

Suzana Kerliu,  Kosova Task Force for Cancer, USA

David Berd,  Avax Technologies Inc, USA

Jennifer Wu,  Medical University of South Carolina, USA

Alavi Abass,  University of Pennsylvania, USA

Josef Bodor,  Institute of Experimental Medicine, USA

Meena Katdare,  Hampton University Skin of Color Reserach Institute, USA

Jiabin Tang,  Memorial Sloan Kettering Cancer Center, USA

Maria Athanassiou,  The Cancer Cure, USA

Gilberto Lopes,  Johns Hopkins University, USA

Pietro Taverna,  Astex Pharmaceuticals, Pleasanton, USA

David Boothman,  University of Texas Southwestern Medical Center, USA

E Shyam P Reddy,  Morehouse School of Medicine, USA

Qi-Huang Zheng,  Indiana University School of Medicine, USA

Brendan Frett,  University of Arizona College of Pharmacy, USA

Pragati Katiyar,  Frederick National Laboratory for Cancer Research, USA

Hosam Elbaz,  University of Michigan, USA

Ashish Kamat,  MD Anderson Cancer Center, USA

Vita Golubovskaya,  ProMab Biotechnologies, Inc, USA

B Sharma,  ScyTek, Celprogen Inc, USA

Gregory Hale,  Johns Hopkins University, USA

Goodwin Jinesh,  UT MD Anderson Cancer Center, USA

Gregory Hale,  Johns Hopkins University, USA

Jorge Augusto Borin Scutti,  MD Anderson Cancer Center, USA

Shuang Yan,  Johns Hopkins University, USA

Fares Nigim,  Massachusetts General Hospital, USA

Richard Huhn,  Biothera, USA

Parul Mishra,  UMass Medical School, USA

Barbara Guinn,  University of Bedfordshire, United Kingdom

Warner Ben Franklin,  The University of Texas Health Science Center, USA

Shaillay Dogra,  Vishuo Biomedical Pte Ltd, Singapore

Sivakumar Gowder,  Qassim University, Saudi Arabia

Xiang-Yun Zong,  Shanghai Jiao Tong University, China

Mohamed Laban,  Ain Shams University, Egypt

Nithin B. Boppana,  Belcher Pharmaceuticals, United States

Francesco Fiorica,  University Hospital of Ferrara, Italy

Waheed yousry Gareer,  National Cancer Institute, Egypt

Safdar shah,  Sheikh Zayed Hospital, Pakistan

Amal Khalifa,  Dammam University Hospital, Egypt

Zeinab Elsayed,  Ain Shams University, Egypt

Leandro Thiago,  National Cancer Institute, Brazil

Christopher Wong,  Liverpool Hope University, United Kingdom

Tomohiro Chiba,  Kyorin University School of Medicine, Japan

Hiromasa Morikawa,  The Institute of Karolins, Japan

Nikolai Zhelev,  Abertay University, United Kingdom

Sherif Abdelwahab,  Ain Shams University, Egypt

Hami Ashraf,  Mashhad University of medical sciences, Iran

Marcelo Cruz,  St Joseph Hospital, Brazil

Amr Sakr,  Cairo University, Egypt

Ahmed Adel Hassan,  Zagazig university, Egypt

Yasser Sallam,  Cairo University, Egypt

Mallikarjunarao Kasam,  Smart Medical Physicists and Consultants, USA

Kyriakos Souliotis,  University of Peloponnese, Greece

Mohamed Mahmoud,  Taibah University, Saudi Arabia

Kursad Turksen,  Ottawa Hospital Research Institute, Canada

Timothy Allen,  The University of Texas, USA

Mohsen Mokhtar,  Cairo University, Egypt

Nabil Mobarek,  Menoufeya University, Egypt

Feng-Chi Ho,  Guangzhou East Cancer Hospital, Taiwan

Muhyi Al-Sarraf,  Royal College of Physicians of Canada, Canada

Rajeev Shrivastava,  Aditya Birla Memorial Hospital, India

Dalia Darwish,  Cairo University, Canada

Zafar Mahmood,  University of Wuerzburg, Germany

Yin-Long Yang,  Wenzhou Medical University, China

Luis Moreno Sanchez,  Cancer Center - Metropolitan Hospital of Santiago, Dominican Republic

Daniela Capdepon,  Universidad del Salvador, Argentina

Ahmed Adel Seida,  Cairo University, Egypt

Mahmoud Ellithy,  Ain Shams University, Egypt

Parveen Shahida Akhtar,  National Institute of cancer Research, Bangladesh

Qazi Mushtaq Hussain,  Dhaka Medical College, Bangladesh

Rajesh Singh,  University of Mysore, India

vishwas Pai,  Kerudi Cancer Hospital and Research Centre, India

Kemal Atahan,  Izmir Ataturk, Turkey

Or Cohen-Inbar,  Gamma-Knife Center University of Virginia Health Care Center, Virginia

Kurtulus Gokduman,  Istanbul Beykent University, Turkey

Parthasarathy Chandrakesan,  University of Oklahoma Health Sciences Center, USA

Muhammad Asaduzzaman,  University of Dhaka, Bangladesh

Chunde,  Karolinska Institutet, Sweden

Ragaa tahtawy,  National Cancer Institute, Egypt

Marika Bajc,  University Hospital Lund, Sweden

Ling Li,  Beckman Research Institute of City of Hope, USA

Muhamamd Wasim,  University of Veterinary and Animal Sciences, Pakistan

Abraham Chandy,  Karunya University, India

Durairaj Sekar,  Narayana Medical College and Hospital, India

Tianhao Sun,  The University of Hong Kong, China

Peter Hu,  University of Texas Medical Branch, USA

Mohammaed Rahimi Gorji,  Ghent University, Belgium

Eda Alemdar,  Goce Delcev University, Macedonia

Journal Menu

  • Aim and Scope
  • Editorial Board
  • Articles in Press
  • Current Issue
  • Archive

Downloads

  • Cover Letter
  • Manuscript Template

Journal metrics

Publication Duration 28 Days
Acceptance rate 36%
Total Publications 1891
Editorial board members 1002
Impact Factor 2.746
IC Value 4.78
Article Processing Fee 499 USD

PubMed Indexed Articles


EC Pharmacology and Toxicology

LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology

LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology

LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

Subscribe To Our Newsletter

ECronicon Journal

  • About
  • Privacy Policy
  • Contact Us
  • Publication Process

Our Services

  • Author Guidelines
  • Editor Guidelines
  • Reviewer Guidelines

Quick Links

  • Advertising
  • Reprints

Information

  • Phone +44 20 3769 9658
  • Email editor@ecronicon.uk
  • Address 32, 19-21 Crawford Street London W1H 1PJ United Kingdom

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.org

Colored Stripes